Summary:
- Sanofi, a leading pharmaceutical company, has announced plans to acquire Blueprint Medicines, a biotechnology company focused on developing targeted therapies for rare diseases.
- The acquisition will expand Sanofi's portfolio in the field of rare immunological diseases, providing access to Blueprint Medicines' expertise and early-stage pipeline in immunology.
- This strategic move will allow Sanofi to strengthen its position in the rare disease market and potentially bring new and innovative treatments to patients suffering from rare immunological conditions.